Duquesne Family Office LLC bought NTRA · INSIDER
Data sources SEC Form 4 1h ago
House PTR 1h ago
SEC 13F 1h ago
Robinhood Chain 1h ago
SEC 13F / ADD Verified data
DO 13F filer · Natera, Inc. · Natera Inc
○ Watch NTRA○ Watch filer
Side BUY
Δ value $33K
Shares 122.7K
Price $0.27
Executed Not disclosed
Disclosed Aug 14, 2026 Customize layout
NTRA · daily Yahoo Finance chart API
◉ This trade, on the day it was made▼ Disclosure● Material company filing◯ Other disclosed buy◯ Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Insider Score Experimental signal Transaction type +6 / 20
ADD
Relative size +2 / 25
$33K quarter-over-quarter change
Filing timing 0 / 15
Not applicable — 13F reports quarter-end holdings, execution dates are not disclosed
Historical behavior +8 / 15
First recorded trade by this actor in this security
Frequency & clustering 0 / 15
No clustered activity in the dataset
Market events 0 / 10
No material company filing within 60 days after the trade
Other disclosed activity · NTRA Score Actor Security Side Value Executed Disclosed Lag Source Evidence 13 FJ Fesko John PRESIDENT, CHIEF BUS. OFFICER
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $2,717 7 sh
Nov 2, 2026 Nov 4, 2026
Verified data Read directly from the primary public document; every field below is as reported by the filer.
Source
Publisher U.S. Securities and Exchange Commission (EDGAR)
Document ID 0001536411-26-000006 Timestamps
Event (reported) Not reported
Published Aug 14, 2026
Ingested by INSIDER Nov 4, 22:39 UTC
Last re-read Nov 10, 08:27 UTC Extracted facts
Filer Duquesne Family Office LLC
Role 13F filer
Transaction ADD
Asset Natera Inc
Ticker NTRA
Shares 122.7K
Price per share $0.27
Value $33,307
Owned after transaction 3.19M shares What this establishes Duquesne Family Office LLC reported this position change in a quarterly 13F holdings report. 13F shows quarter-end positions only — it does not say when during the quarter shares were bought or sold.
Extraction
Method 13F information table XML
Confidence 1.00
13F filer Duquesne Family Office LLCcik:0001536411
Issuer Natera, Inc.cik:0001604821 Revision history · 0 No field has changed since this record was first ingested.
No records No material filings recorded for this issuer.
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
16 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $176K 432 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
16 FJ Fesko John PRESIDENT, CHIEF BUS. OFFICER
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $118K 295 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
19 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $316K 760 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $49K 120 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
16 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $166K 408 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 SJ Sheena Jonathan Director, CO-FOUNDER
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $44K 109 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $33K 80 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
16 BB Brophy Michael Burkes CHIEF FINANCIAL OFFICER
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $127K 317 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 RD Rabinowitz Daniel SEC. AND CHIEF LEGAL OFFICER
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $2,717 7 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
16 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $164K 410 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $50K 120 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
16 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $213K 520 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 BB Brophy Michael Burkes CHIEF FINANCIAL OFFICER
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $3,104 8 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
22 CL Chapman Steven Leonard Director, CEO AND PRESIDENT
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $1.19M 2,866 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
16 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $100K 240 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
19 RM Rabinowitz Matthew Director, EXECUTIVE CHAIRMAN
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $293K 731 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 CL Chapman Steven Leonard Director, CEO AND PRESIDENT
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $8,146 21 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 RM Rabinowitz Matthew Director, EXECUTIVE CHAIRMAN
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $6,599 17 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
13 MS Moshkevich Solomon PRESIDENT, CLINICALDIAGNOSTICS
NTRA Natera, Inc. Open-market sale · 10b5-1 plan
SELL $3,494 9 sh
Nov 2, 2026 Nov 4, 2026traded Nov 2, 2026
+2d SEC Form 4 Evidence
Evidence Close
